Assessing overall asthma control with budesonide/formoterol maintenance + relief in moderate/severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma Source: Eur Respir J 2008; 31: 982-989 Year: 2008
Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018
Formoterol Turbuhaler® reduces the need for relief medication in children with mild to moderate asthma and improves quality of life Source: Eur Respir J 2001; 18: Suppl. 33, 291s Year: 2001
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011
Emergency visits for asthma: asthma exacerbations or poor asthma control? Source: Eur Respir J 2004; 24: Suppl. 48, 598s Year: 2004
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Perceived bronchodilator efficacy during severe asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006